Targets › AGTR2
1 program from 1 company in 1 trial: 1 Phase 2; Respiratory; next expected readout May 2027.
Receptor for angiotensin II, a vasoconstricting peptide. Primarily signals via a non-canonical G protein- and beta-arrestin independent pathways. (UniProt, P50052)
Open in Phaseline: the race on AGTR2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Vicore Pharma | Buloxibutid Angiotensin II type 2 receptor agonist | AGTR2 | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | May 2027 |
Idiopathic Pulmonary Fibrosis (IPF) (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.